98%+ Purity Cyproterone Acetate Pure Powder
Product Details:
| Cyproterone Acetate Powder Information | ||
| Cyproterone Acetate Price | 100g | According to your needs |
| 500g | According to your needs | |
| 1000g | According to your needs | |
| Steroid packaging | Special stealth packaging through Customs | |
| Delivery time | About 7 days | |
| Shipping | EMS, Hongkong Post, DHL, TNT, Fedex | |
| Payment terms | WU, MG, Bitcoin, T/T | |
| Minimum order | 10g powder | |
98%+ Purity Cyproterone Acetate Pure Powder
Cyproterone Acetate Details:
Product name: Cyproterone acetate
Alias: Androcur; CCRIS 4385; Cyprostat; Cyproteron acetate; Cyproteron-R acetate; Cyproterone 17-O-acetate; Cyproterone 17alpha-acetate; HSDB 3592; NSC 81430; NSC-81430
CAS: 427-51-0
EINECS Number: 207-048-3
Formula: C24H29ClO4
MW: 416.9377
Density: 1.27g / cm3
Boiling point: 525.9 ° C at 760 mmHg
Flash Point: 177.6 ° C
Vapor Pressure: 3.78E-11mmHg at 25 ° C
Uses: anti-androgen for the treatment of men with benign prostatic hyperplasia, and can be used as a male contraceptive
Assay:99%
Appearance:white crystalline powder
Cyproterone Acetate Specifications:
COA
| Analysis Test | Specification | Result |
| Description | white crystalline powder,odorless | Conforms |
| Solubility | Easily soluble in water, unsoluble in ethanol | Conforms |
| PH | 6.0~7.5 | 6.9 |
| Solution clarity and color | solution should be clear and colorless | Conforms |
Related substances | 5'CMP 0.3% | 0.01% |
| Simple impurity | 0.03% | |
| Total other impurity | 0.10% | |
| Chloride | 0.05% | Conforms |
| Anti Estrogen Steroids Cyproterone Acetate 427 - 51 - 0 For Prostate Cancers | ||
| Ammonium | 0.05% | Conforms |
| Fe | 0.01% | Conforms |
| Phosphate | 0.1% | Conforms |
| Loss on drying | ≤6.0% | 1.3% |
| Heavy metals | 0.002% | Conforms |
| Arsenide | 0.0001% | Conforms |
| Bacterial Endotoxins | 0.3EU/mg | Conforms |
| Microbial Limit | Conforms | Conforms |
| Assay(on dried basis) | ≥98.0% | 98.8% |
Cyproterone Acetate Descriptions:
Cyproterone acetate (INN, USAN, BAN, JAN), sometimes abbreviated asnCPA, and sold under brand names such as Androcur and Cyprostat, isna synthetic steroidal antiandrogen drug with additional progestogennand antigonadotropic properties. Its primary action is to suppressnthe activity of the androgen hormones such as testosterone and itsnmore potent metabolite dihydrotestosterone (DHT) in the body,neffects which it mediates via competitive antagonism of thenandrogen receptor and inhibition of enzymes in the androgennbiosynthesis pathway. The main therapeutic indications ofncyproterone acetate are prostate cancer, benign prostaticnhyperplasia, priapism, hypersexuality (e.g., as a form of chemicalncastration), and other conditions in which androgen actionnmaintains the disease process. In addition, it can also be used tontreat acne and hirsutism in females, and is a common component innhormone therapy for transsexual women.
In addition to its antiandrogen properties, cyproterone acetate hasnweak progestogen activity (i.e., it acts like progesterone).nAccordingly, it can be used to treat hot flashes, and is also ancomponent of some combined oral contraceptive pills such asnDianette in the United Kingdom and Diane-35 in other countries suchnas Canada. It is called Dixi-35 in Chile. No form of cyproteronenacetate is available in the United States.
Until the development of leuprorelin, cyproterone acetate was onenof the few drugs used to treat precocious puberty. It was also usednin animal experimentation to investigate the actions of androgensnin fetal sexual differentiation.
Cyproterone Acetate Effects:
CPA has been in use as an antiandrogen since 1964, and was the first antiandrogen introduced for clinical use.It is widely used throughout Europe, and is also used in Canada, Mexico, and other countries. It is not FDA-approved for use in the United States, due to concerns about hepatotoxicity; medroxyprogesterone acetate has been used in this country instead.CPA has been approved for the treatment of prostate cancer, precocious puberty, androgen-related dermatological conditions (such as acne, seborrhea, hirsutism, and androgenic alopecia), and to reduce sex drive in sex offenders.Combination formulations of CPA with ethinyl estradiol (a formulation sometimes referred to as co-cyprindiol) have been available as contraceptives since 1997.Other uses of CPA include the treatment of benign prostatic hyperplasia, priapism, hypersexuality, paraphilias, hot flashes, and hyperandrogenism in women. In addition, with the exception of the United States (where CPA is not available and spironolactone is generally employed instead), CPA is widely used as a component of hormone replacement therapy for trans.
